82 Chapter 3 ST6GALNAC5 ASCL1 LHX8 (B) (A) (C) no CIN n = 469 CIN1 n = 99 CIN2 n = 55 CIN3 n = 70 CxCa n = 3 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 NS *** *** *** Methylation level (sqrt transformed) NS *** *** *** NS ** *** *** SST GHSR ZIC1 (E) (D) (F) 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 NS NS *** *** Methylation level (sqrt transformed) NS NS *** *** NS NS *** *** no CIN n = 469 CIN1 n = 99 CIN2 n = 55 CIN3 n = 70 CxCa n = 3 no CIN n = 469 CIN1 n = 99 CIN2 n = 55 CIN3 n = 70 CxCa n = 3 no CIN n = 469 CIN1 n = 99 CIN2 n = 55 CIN3 n = 70 CxCa n = 3 no CIN n = 469 CIN1 n = 99 CIN2 n = 55 CIN3 n = 70 CxCa n = 3 no CIN n = 469 CIN1 n = 99 CIN2 n = 55 CIN3 n = 70 CxCa n = 3 Supplementary Figure 3.1 Methylation levels increase with severity of underlying cervical disease – subgroup with revision diagnosis. DNA methylation levels of ASCL1 (A), LHX8 (B), ST6GALNAC5 (C), GHSR (D), ZIC1 (E) and SST (F) represented by the square-root transformed Cq-ratios (y-axis) in the different histology categories (x-axis). Differences between histological categories upon Kruskal-Wallis omnibus test, followed by post hoc testing using the Wilcoxon rank-sum test and Bonferroni multiple testing correction: *, p value < 0.05; **, p value < 0.01; ***, p value < 0.001; NS, not significant. o outlier sample. Abbreviations: CIN, cervical intraepithelial neoplasia; CxCa, cervical carcinoma; n, number of; no CIN, women with no histology or normal histology; sqrt, square-root Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; n, number of; N, group size; NILM, negative for intraepithelial lesion or malignancy; NPV, negative predicted value; PPV, positive predicted value; BMD, borderline or mild dyskariosis; ASC-H, atypical squamous cells of undetermined significance-cannot exclude HSIL; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade intraepithelial lesion; HSIL, high-grade intraepithelial lesion
RkJQdWJsaXNoZXIy MjY0ODMw